Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered an in-line revenue quarter with management largely reiterating guidance, highlighted by continued belief that TAVR could reaccelerate with an indication expansion and TMTT will keep growing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Hold Rating on Edwards Lifesciences: Balancing Positive Trends with TAVR Uncertainties
- Texas Instruments, Mondelez downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences price target raised to $75 from $72 at Baird
- Edwards Lifesciences upgraded to Overweight from Neutral at Piper Sandler
- Edwards Lifesciences Reports Strong Q1 Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue